PBAC's latest decision on Thyroxine sodium: Not recommended (2016). Considered for Management of demonstrated thyroid hormone deficiency and suppression of thyrotropin (TSH) for the management of TSH-responsive tumours of the thyroid, in the 25 microgram dose strength.
PBAC outcome
Not recommended
Not applicable
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2015
Submissions
2
2015 → 2016
Eligible population
Elderly patients, patients with ischaemic heart disease, and children requiring thyroxine initiation doses of 25 micrograms.
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Cost-minimisation
ICER note
Cost-minimisation/BIA context only; no formal ICER calculated. PBAC considered cost-effectiveness but did not model an ICER.
Why PBAC said no
Reasons cited in the latest PSD: no unmet clinical need, not cost-effective at proposed price, range of other thyroxine strengths already listed on PBS
Submission history
Nov 2015: Recommended with restriction · Unrestricted